Migraine – Landscape & Forecast – Disease Landscape & Forecast
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP monoclonal antibodies for migraine prevention, oral CGRP receptor antagonists for both the treatment of acute migraine attacks and migraine prevention) and a range of innovative reformulations set for near-term launch in the United States, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost / coverage, and the headwinds posed by low-cost, early-line stand-of-care treatments will be key to the success of current and future players in migraine.
Questions Answered:
- What events will shape the future of the acute / preventive and episodic / chronic market segments?
- How are the anti-CGRP monoclonal antibodies (e.g., Aimovig, Emgality) and oral gepants (i.e., Nurtec ODT / Vydura, Qulipta) being integrated into the generic-dominant migraine prophylaxis market? Which brands will be the most competitive and why?
- What is the dynamic between Ubrelvy and Nurtec ODT in the U.S. market? How are oral gepants being adopted into the triptan-dominant acute segment?
- How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 23 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Total, diagnosed, and drug-treated prevalent cases of episodic and chronic migraine, segmented by acute and prophylactic treatment.
Emerging therapies: Phase II: 7 drugs; Phase III / preregistration: 4 drugs.
Market forecast features: Patient-based market forecast extending through 2031, segmented by brands and generics.
Product Description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement:
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Migraine - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Migraine Key Findings - June 2023
- Key Updates
- June 2023
- May 2023
- March 2023
- Q4 2022
- November 2022
- Q3 2022
- August 2022
- Market Outlook
- Key findings
- Market share of drug classes for the acute treatment of migraine: 2021
- Market share of drug classes for the acute treatment of migraine: 2031
- Market share of drug classes for the prophylactic treatment of migraine: 2021
- Market share of drug classes for the prophylactic treatment of migraine: 2031
- Migraine SWOT analysis
- Market drivers and constraints
- What factors are driving the market for migraine?
- What factors are constraining the market for migraine?
- Market share and treated patients for acute migraine by country: 2021 and 2031
- Market share and treated patients for migraine prophylaxis by country: 2021 and 2031
- Segment-specific trends
- Sales of acute and prophylactic treatments in the episodic and chronic migraine markets: 2021 and 2031
- Drug-class-specific trends
- Major-market sales of key triptans in acute migraine: 2021-2031
- Major-market patient share of key triptans in acute migraine: 2021-2031
- U.S. sales of emerging acute treatments in migraine: 2021-2031
- Anti-CGRP monoclonal antibodies
- CGRP receptor antagonists
- Major-market sales of CGRP-targeted therapies for migraine prophylaxis: 2021-2031
- Major-market patient share of CGRP-targeted therapies for migraine prophylaxis in episodic migraine: 2021-2031
- Major-market patient share of CGRP-targeted therapies for migraine prophylaxis in chronic migraine: 2021-2031
- Major-market sales of other prophylactic treatments in migraine: 2021-2031
- Major-market patient share of other prophylactic treatments in migraine: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions: acute migraine
- Market forecast dashboard: acute migraine
- Market forecast assumptions: migraine prophylaxis
- Market forecast dashboard: migraine prophylaxis
- Etiology and pathophysiology
- Disease overview
- Anatomy of the brain
- Genetic factors
- Environmental factors: migraine triggers
- Select precipitating (trigger) factors associated with migraine
- Key pathways and drug targets
- Substances involved in neurotransmission in migraine
- Role of select 5-HT receptor subtypes in migraine
- Neurogenic inflammation in migraine
- Neurogenic inflammation in migraine headache
- Progression of spreading depression and oligemia believed to be associated with migraine aura
- Other processes involved in migraine
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Sources used for total prevalent cases of migraine
- 12-month total migraine cases in the major pharmaceutical markets: 2021-2031
- Disease definition
- Methods
- Sources used for total prevalent cases of episodic migraine
- Total 12-month episodic migraine cases in the major pharmaceutical markets: 2021-2031
- Disease definition
- Sources used for total prevalent cases of chronic migraine
- Total 12-month chronic migraine cases in the major pharmaceutical markets: 2021-2031
- Disease definition
- Methods
- Sources used for frequency of episodic migraine attacks
- Total 12-month episodic migraine cases according to frequency of attacks in the major pharmaceutical markets: 2021-2031
- Disease definition
- Methods
- Sources used for total episodic migraine events
- Total 12-month episodic migraine events in the major pharmaceutical markets: 2021-2031
- Diagnosed prevalent cases of episodic migraine: 2021-2031 (thousands)
- Diagnosed prevalent cases of chronic migraine: 2021-2031 (thousands)
- Acute migraine treatment
- Acutely drug-treated prevalent cases of episodic migraine: 2021-2031 (thousands)
- Acutely drug-treated prevalent cases of chronic migraine: 2021-2031 (thousands)
- Migraine prophylaxis
- Prophylactically drug-treated prevalent cases of episodic migraine: 2021-2031 (thousands)
- Prophylactically drug-treated prevalent cases of chronic migraine: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for migraine
- Key current therapies: acute treatment
- Overview
- Mechanism of action of key current drug classes used for the acute treatment of migraine
- Current treatments used for the acute treatment of migraine
- Market events impacting the use of key current acute therapies in migraine
- Advantages and disadvantages of sumatriptan
- Expert insight: sumatriptan
- Advantages and disadvantages of Treximet
- Advantages and disadvantages of rizatriptan
- Advantages and disadvantages of frovatriptan
- Advantages and disadvantages of zolmitriptan
- Expert insight: zolmitriptan
- Advantages and disadvantages of other triptans
- Advantages and disadvantages of Reyvow
- Key results from select clinical trials investigating Reyvow for the acute treatment of migraine
- Ongoing clinical development of Reyvow
- Expert insight: Reyvow
- Key results from select clinical trials investigating Ubrelvy for the acute treatment of migraine
- Ongoing clinical development of Ubrelvy
- Expert insight: Ubrelvy
- Advantages and disadvantages of Nurtec ODT / Vydura
- Key results from select clinical trials investigating Nurtec ODT / Vydura for the acute treatment of migraine
- Key results from clinical trials investigating Nurtec ODT / Vydura for the prophylactic treatment of migraine
- Ongoing clinical development of Nurtec ODT / Vydura
- Expert insight: Nurtec ODT / Vydura
- Dihydroergotamine mesylate
- Advantages and disadvantages of dihydroergotamine mesylate
- Expert insight: DHE
- Trudhesa
- Advantages and disadvantages of Trudhesa
- Key results from clinical trials investigating Trudhesa for the acute treatment of migraine
- Expert insight: Trudhesa
- Advantages and disadvantages of Elyxyb
- Key results from clinical trials investigating Elyxyb for the acute treatment of migraine
- Expert insight: Elyxyb
- Advantages and disadvantages of prescription NSAIDs and nonnarcotic analgesics
- Advantages and disadvantages of narcotic prescription analgesics
- Key current therapies: prophylactic treatment
- Overview
- Mechanism of action of key current drug classes used for the prophylactic treatment of migraine
- Current treatments used for the prophylactic treatment of migraine
- Market events impacting the use of key current preventive therapies in migraine
- Advantages and disadvantages of topiramate
- Advantages and disadvantages of divalproex
- Advantages and disadvantages of Botox
- Advantages and disadvantages of Aimovig
- Key results from select clinical trials investigating Aimovig for the prophylactic treatment of migraine
- Ongoing clinical development of Aimovig
- Expert insight: Aimovig
- Advantages and disadvantages of Ajovy
- Key results from select clinical trials investigating Ajovy for the prophylactic treatment of migraine
- Ongoing clinical development of Ajovy
- Advantages and disadvantages of Emgality
- Key results from select clinical trials investigating Emgality for the treatment of migraine
- Ongoing clinical development of Emgality
- Expert insight: Emgality
- Advantages and disadvantages of Vyepti
- Key results from select clinical trials investigating Vyepti for the treatment of migraine
- Ongoing clinical development program of Vyepti
- Qulipta
- Advantages and disadvantages of Qulipta
- Key results from clinical trials investigating Qulipta for the prophylactic treatment of migraine
- Ongoing clinical development of Qulipta
- Expert insight: Qulipta
- Advantages and disadvantages of beta blockers
- Advantages and disadvantages of amitriptyline
- Advantages and disadvantages of calcium channel blockers
- Medical practice
- Overview
- Factors influencing drug selection in migraine
- Treatment decision tree for the acute treatment of migraine: United States
- Treatment decision tree for the prophylactic treatment of migraine: United States
- Treatment decision tree for the acute treatment of migraine: Europe
- Treatment decision tree for the prophylactic treatment of migraine: Europe
- Treatment decision tree for the acute treatment of migraine: Japan
- Treatment decision tree for the prophylactic treatment of migraine: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in migraine
- Top unmet needs in migraine: current and future attainment
- Expert insight: unmet need in migraine
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for migraine
- Estimated launch dates of key emerging therapies for the treatment of migraine
- AXS-07
- AXS-07 profile
- Analysis of clinical development program for AXS-07
- Expert insight: AXS-07
- Expectations for launch and sales opportunity of AXS-07 in migraine
- Qtrypta profile
- Analysis of clinical development program for Qtrypta
- Expert insight: Qtrypta
- Expectations for launch and sales opportunity of Qtrypta (M-207) in migraine
- STS101
- STS101 profile
- Expert insight: STS101
- Expectations for launch and sales opportunity of STS101 in migraine
- Zavegepant profile
- Analysis of clinical development program for zavegepant
- Expert insight: zavegepant
- Expectations for launch and sales opportunity of zavegepant in migraine
- Early-phase pipeline analysis
- Select compounds in early-phase development for the acute treatment of migraine
- Select compounds in early-phase development for the prophylactic treatment of migraine
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in migraine: United States
- General reimbursement environment: United States
- Key market access considerations in migraine: EU5
- General reimbursement environment: EU5
- Key market access considerations in migraine: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Migraine bibliography
- Key Findings
Shayan Chakraborty is a senior healthcare research and data analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this role, he oversees the team’s syndicated research stream in neurology, with a core focus on migraine. He has several years of experience working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, vaccines, specialty pharma, and rare diseases.
Prior to joining Clarivate, he was an assistant manager at WNS Global Services, where he was responsible for providing analytical and forecasting support to Global Vaccine Business Insight partners for early-phase products. He holds a bachelor’s degree in biotechnology from West Bengal University of Technology and a master’s degree in biotechnology and biochemical engineering from the Indian Institute of Technology, Kharagpur. Currently, he is pursuing India’s first full-time online bachelor’s degree in data science and programming from the Indian Institute of Technology, Madras.